INGELHEIM, Germany, April 16, 2026

Boehringer Ingelheim has announced the publication of Phase 1b Beamion LUNG-1 trial results for zongertinib (HERNEXEOS®) in The New England Journal of Medicine, demonstrating strong efficacy in treatment-naïve patients with HER2-mutant advanced non-small cell lung cancer (NSCLC). The findings highlight the potential of zongertinib as a first-line targeted therapy, addressing a critical unmet need in a patient population with historically limited treatment options.

Strong Clinical Efficacy Demonstrated in Phase 1b Trial

The Beamion LUNG-1 study evaluated 74 patients with HER2-mutant advanced NSCLC, showing remarkable clinical outcomes across multiple efficacy endpoints. The trial reported a confirmed objective response rate (ORR) of 76%, including 11% complete responses and 65% partial responses, indicating a high level of tumor reduction.

Additionally, the therapy demonstrated durable responses, with a median duration of response (mDoR) of 15.2 months and a median progression-free survival (mPFS) of 14.4 months, highlighting sustained clinical benefit. Importantly, the treatment showed activity in patients with brain metastases, where 47% achieved intracranial response, addressing a major challenge in advanced lung cancer treatment. These results position zongertinib as a highly effective targeted therapy in a difficult-to-treat population.

Favorable Safety Profile and Targeted Mechanism

Advertisement

cGxPJobs Banner

Zongertinib is an irreversible tyrosine kinase inhibitor (TKI) designed to selectively target HER2 mutations while sparing wild-type EGFR, reducing off-target toxicities. The safety profile observed in the study was favorable, with most adverse events classified as low-grade, and only a small proportion of patients requiring dose reductions or discontinuation.

This targeted approach enables precision oncology treatment, directly addressing the molecular drivers of cancer while minimizing side effects. HER2 mutations, present in approximately 2–4% of NSCLC cases, are associated with aggressive disease and poor prognosis, making effective targeted therapies essential. The ability of zongertinib to deliver high efficacy with manageable safety reinforces its role as a potential first-in-class oral therapy in this setting.

Regulatory Progress and Global Development Momentum

Zongertinib has already received accelerated approval from the U.S. FDA for patients with HER2-mutant advanced NSCLC, based on its strong response rates and durability of benefit. The therapy has also been granted Breakthrough Therapy Designation and selected for the FDA Commissioner’s National Priority Voucher program, highlighting its importance in addressing urgent unmet medical needs.

Beyond the United States, zongertinib has received conditional approval in China and full approval in Japan, making it the first orally administered targeted therapy for HER2-mutant NSCLC in these regions. Ongoing clinical trials are evaluating the therapy across earlier treatment lines and additional solid tumor indications, further expanding its global potential. These developments underscore the importance of GxP-compliant clinical research, regulatory alignment, and manufacturing excellence in bringing innovative oncology therapies to market.

Implications for Precision Oncology and Patient Care

The publication of these results in a leading medical journal highlights a significant advancement in precision oncology, where treatments are tailored to specific genetic mutations. With lung cancer remaining the leading cause of cancer-related mortality worldwide, the development of targeted therapies like zongertinib is critical for improving patient outcomes.

The therapy’s ability to deliver high response rates, durable outcomes, and activity in brain metastases represents a meaningful step forward in addressing the challenges of advanced NSCLC. As the field continues to evolve, innovations such as zongertinib are expected to play a key role in transforming treatment paradigms and improving survival rates for patients with rare genetic mutations.

The Boehringer Ingelheim zongertinib program represents a major breakthrough in HER2-mutant NSCLC treatment, combining strong clinical efficacy, favorable safety profile, and robust regulatory momentum. With its potential as a first-line targeted therapy, zongertinib is well-positioned to reshape the treatment landscape and address critical unmet needs in lung cancer care, reinforcing Boehringer Ingelheim’s leadership in oncology innovation.

Source: Boehringer Ingelheim press release